Filter
70
Filtered Results: 70
Text search:
Global
Pharma
Health
Fund
E.V.
Featured
Recommendations
3
New Publications
22
Language
Document type
No document type
34
Studies & Reports
20
Guidelines
7
Manuals
4
Situation Updates
3
Training Material
1
Strategic & Response Plan
1
Countries / Regions
Kenya
5
Global
4
Nigeria
3
Uganda
2
India
2
Tajikistan
1
Ukraine
1
Turkey
1
Ghana
1
Syria
1
Burkina Faso
1
Mongolia
1
Philippines
1
Africa
1
Cambodia
1
Jordan
1
Congo, Democratic Republic of
1
Western and Central Europe
1
Lebanon
1
Bangladesh
1
Russia
1
Ethiopia
1
Iraq
1
Myanmar / Burma
1
Madagascar
1
Eswatini/ Swaziland
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Drugs & Medical Equipment
8
Studies & Reports
6
Policies
4
COVID-19
3
Policies & Guidelines HIV & TB
3
Guidelines
3
Medical Devices & Equipment
2
Gynaecology & Obstetrics
2
Maternal Health
2
Laboratory Quality Assurance
2
Pharmacy & Technologies
2
Paediatrics
1
Cancer Treatment & Resources
1
Infection Control & Prevention (IPC)
1
Women & Child Health
1
Humanitarian Crisis
1
Other
1
WASH
1
Surgery & Anaesthesia
1
Health Systems
1
Primary Health Care
1
HIV & STI
1
Age & Elderly
1
Neonatal Care
1
Reproductive Health
1
Global Health
1
TB
1
Toolboxes
Local Action
2
General Reports
2
Clinical Aspects, Treatment & Prevention
2
Country specific
2
Curricula & Core Competencies
2
Studies
2
Country Specific
2
Country specific documents
2
Global Impact: Socio-economic, health services, TB & HIV
2
Medical & Community Masks
2
Self-care
2
Essential Medicines
2
Prices and Patents
2
Falsified & Substandard
2
Quality Assurance
2
Drug resistant TB
2
Human Rights & the Right to Health
2
Antiretroviral Treatment ART
2
Lobby and Advocacy
2
ART Drug Resistance
1
Surveillance
1
IPC
1
Europe
1
Treatment & Prevention
1
Preparedness, Response & Risk Communication
1
Prevention & Control
1
Introduction to Global Health
1
Concepts of Global Health
1
Advocacy
1
Health Equity & Equality
1
Training
1
Sustainable Development Goals
1
International
1
General
1
Best Practice
1
Public Health
1
For Parents & Children
1
Educational Settings
1
Hospital Readiness/Essential Health Services
1
Hygiene
1
Resuscitation
1
Reports & Studies
1
Studies & Reports
1
Risk Factors
1
Women
1
Global Overview
1
General
1
Alzheimer's Disease & Dementia
1
General
1
Assessment & Response
1
Training
1
Research & Access
1
Vision Loss & Blindness
1
Global Health Institutions and Stakeholders
1
Reports & Studies
1
Eastern Europe and central Asia
1
Zule et al. Harm Reduction Journal (2018) 15:44 https://doi.org/10.1186/s12954-018-0249-3
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...
In 2017, 3.6 million of the estimated 10 million people with TB worldwide were “missed” by national TB programmes (NTPs). Two thirds of them are thought to access TB treatment of questionable quality from public and private providers who are not engaged by the NTP. The quality of care provided i...
Technical Update
HIV Treatment
July 2017
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet...
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ...
Updated 28 December 2020
J of Pharm Policy and Pract 14, 27 (2021). https://doi.org/10.1186/s40545-021-00309-8
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to...
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...
Why bold action against inequalities is needed to en AIDS, stop COVID-19 and prepare for future pandemics
It outlines key achievements, needs and opportunities for intervention in the field of rehabilitation in Ukraine. The content of this document is a snapshot in time – not an in-depth analysis of the entire rehabilitation sector. The analysis focuses on rehabilitation policy and governance, service...
Front. Public Health, 30 April 2021 | https://doi.org/10.3389/fpubh.2021.628744
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease
(CD). T. cruzi is transmitted by triatomine insects, congenitally, through uncontrolled blood donations and organ transplants,
and via consumption of food or drink contaminated by triatomi...
